Université d'Auvergne Clermont1 | CNRS

.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).

TitleNomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
Publication TypeJournal Article
Year of Publication2016
AuthorsGanne-Carrié, N., R. Layese, V. Bourcier, C. Cagnot, P. Marcellin, D. Guyader, S. Pol, D. Larrey, V. De Lédinghen, D. Ouzan, F. Zoulim, D. Roulot, A. Tran, J. - P. Bronowicki, J. - P. Zarski, G. Riachi, P. Calès, J. - M. Péron, L. Alric, M. Bourlière, P. Mathurin, J. - F. Blanc, A. Abergel, L. Serfaty, A. Mallat, J. - D. Grangé, P. Attali, Y. Bacq, C. Wartelle, T. Dao, Y. Benhamou, C. Pilette, C. Silvain, C. Christidis, D. Capron, B. Bernard-Chabert, D. Zucman, V. Di Martino, J. - C. Trinchet, P. Nahon, and F. Roudot-Thoraval
Corporate AuthorsANRS CO12 Cirvir study group
JournalHepatology (Baltimore, Md.)
Date Published2016 Jun 27
ISSN1527-3350
Abstract

BACKGROUND: To develop an individualized score for predicting hepatocellular carcinoma (HCC) in patients with hepatitis C (HCV)-compensated cirrhosis.

METHODS: Among 1,323 patients with HCV-cirrhosis enrolled in the French prospective ANRS CO12 CirVir cohort, 720 and 360 were randomly assigned to training and validation sets, respectively. Cox multivariate model was used to predict HCC, after which a nomogram was computed to assess individualized risk.

RESULTS: During follow-up (median: 51.0 months), 103 and 39 patients developed HCC in the training and validation sets, respectively. Five variables were independently associated with occurrence of HCC: age > 50 years (HR 1.94, 95%CI [1.16; 3.25], p=0.012); past excessive alcohol intake (HR 1.55, 95%CI [1.02; 2.36], p=0.041); low platelet count (< 100 Giga/mm3: HR 2.70, 95% CI [1.62; 4.51], p < 0.001; [100; 150] Giga/mm3: HR 1.87, 95%CI [1.10; 3.18], p=0.021); GGT above the upper limit of normal (HR 1.96, 95%CI [1.11; 3.47], p=0.021); and absence of a sustained virological response during follow-up (HR 3.02, 95%CI [1.67; 5.48], p<0.001). An 11-point risk score was derived from the training cohort and validated in the validation set. Based on this score, the population was stratified into three groups, in which HCC development gradually increased, from 0% to 30.1% % at 5 years for patients with the lowest (≤ 3) and highest (≥ 8) scores (p < 0.001). Using this score, a nomogram was built enabling individualized prediction of HCC occurrence at 1, 3 and 5 years.

CONCLUSIONS: This HCC score can accurately predict HCC at an individual level in French patients with HCV-cirrhosis. This article is protected by copyright. All rights reserved.

DOI10.1002/hep.28702
Alternate JournalHepatology